A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 17 Aug 2018 Planned End Date changed from 25 Sep 2018 to 1 Dec 2018.
- 17 Aug 2018 Planned primary completion date changed from 25 Sep 2018 to 1 Dec 2018.